Nivalis
Newsroom

Latest News

  • 7
    Oct.
  • Mon, 13 Feb 17 16:05:00 -0500

    Nivalis Therapeutics Reports Fourth Quarter and Full-Year 2016 Financial Results

  • Download
  • 7
    Oct.
  • Thu, 12 Jan 17 16:10:00 -0500

    Nivalis Therapeutics Announces Corporate Restructuring

  • Download
  • 7
    Oct.
  • Tue, 03 Jan 17 18:00:00 -0500

    Nivalis Therapeutics Announces Review of Strategic Alternatives

  • Download
  • 7
    Oct.
  • Mon, 28 Nov 16 16:05:00 -0500

    Nivalis Therapeutics Announces Results from Phase 2 Clinical Trial of Cavosonstat for Treatment of Cystic Fibrosis

  • Download
  • 7
    Oct.
  • Mon, 14 Nov 16 16:05:00 -0500

    Nivalis Therapeutics Announces Completion of Enrollment in Second Phase 2 Study of Cavosonstat for Treatment of Cystic Fibrosis

  • Download
  • 7
    Oct.
  • Mon, 07 Nov 16 16:05:00 -0500

    Nivalis Therapeutics Reports Third Quarter 2016 Financial Results

  • Download
  • 7
    Oct.
  • Thu, 03 Nov 16 16:05:00 -0400

    Nivalis Therapeutics Announces Appointment of Cynthia Smith to Board of Directors

  • Download
  • 7
    Oct.
  • Wed, 02 Nov 16 16:05:00 -0400

    Nivalis Therapeutics to Present at Two Upcoming Investor Conferences

  • Download
  • 7
    Oct.
  • Tue, 06 Sep 16 07:30:00 -0400

    Nivalis Therapeutics to Present at Two Upcoming Investor Conferences

  • Download
  • 7
    Oct.
  • Mon, 01 Aug 16 16:05:00 -0400

    Nivalis Therapeutics Reports Second Quarter 2016 Financial Results

  • Download
  • 7
    Oct.
  • Thu, 07 Jul 16 07:00:00 -0400

    Nivalis Therapeutics Announces Completion of Enrollment in Phase 2 Study of N91115 for Treatment of Cystic Fibrosis

  • Download
  • 7
    Oct.
  • Wed, 06 Jul 16 16:05:00 -0400

    Nivalis Therapeutics to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference

  • Download
  • 7
    Oct.
  • Wed, 15 Jun 16 07:00:00 -0400

    Nivalis Therapeutics to Present at the JMP Securities Life Sciences Conference

  • Download
  • 7
    Oct.
  • Wed, 01 Jun 16 07:00:00 -0400

    Nivalis Therapeutics to Present at the Jefferies 2016 Healthcare Conference

  • Download
  • 7
    Oct.
  • Mon, 16 May 16 16:05:00 -0400

    Nivalis Therapeutics Announces First Patient Dosed in Second Phase 2 Study of N91115 for Treatment of Cystic Fibrosis

  • Download
  • 7
    Oct.
  • Mon, 02 May 16 16:05:00 -0400

    Nivalis Therapeutics Reports First Quarter 2016 Financial Results

  • Download
  • 7
    Oct.
  • Fri, 22 Apr 16 16:05:00 -0400

    Nivalis Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

  • Download
  • 7
    Oct.
  • Mon, 18 Apr 16 07:00:00 -0400

    Nivalis Therapeutics Appoints David Rodman, MD as Chief Medical Officer and Executive Vice President of Discovery

  • Download
  • 7
    Oct.
  • Tue, 05 Apr 16 08:00:00 -0400

    Nivalis Therapeutics Reaches 50 Percent Enrollment Milestone in Phase 2 Clinical Trial in Cystic Fibrosis

  • Download
  • 7
    Oct.
  • Mon, 07 Mar 16 16:05:00 -0500

    Nivalis Therapeutics Expands N91115 Clinical Development Program in Cystic Fibrosis

  • Download

Publications

  • May 15, 2015

    A Novel Therapeutic Target in Asthma: Translational Evidence for Inhibition of...

    View Poster
  • May 15, 2015

    Enhanced CFTR modulation with a S-nitrosoglutathione reductase inhibitor...

    View Poster
  • October 9, 2014

    Safety, Tolerability, and Pharmacokinetics of the Oral S-Nitrosoglutathione Reductase...

    View Poster
  • October 9, 2014

    Safety, Tolerability, and Pharmacokinetics of the Intravenous...

    View Poster
  • October 4, 2014

    Pharmacological Correction and Acute Inhibition of GSNOR Results in Improved In Vitro...

    View Poster
  • October 4, 2014

    Neutrophil Elastase-Mediated CFTR Damage is Rescued by Intracellular Bioavailable GSNO

    View Poster

Leaving Nivalis.com

Nivalis Therapeutics is not responsible for the content on linked websites.

The document you requested is located on the Journal of Applied Physiology website. A subscription is required to view the document.